BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu H, Jiang Y, Li M, Yu X, Sui D, Fu L. Ginsenoside Rg3 Attenuates Angiotensin II-Mediated Renal Injury in Rats and Mice by Upregulating Angiotensin-Converting Enzyme 2 in the Renal Tissue. Evid Based Complement Alternat Med 2019;2019:6741057. [PMID: 31885658 DOI: 10.1155/2019/6741057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Sui Z, Sui D, Li M, Yu Q, Li H, Jiang Y. Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ. Mol Med Rep 2023;27:84. [PMID: 36866725 DOI: 10.3892/mmr.2023.12971] [Reference Citation Analysis]
2 Jiang Y, Sui D, Li M, Xu H, Yu X, Liu J, Yu Q. Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice. Evid Based Complement Alternat Med 2021;2021:9003603. [PMID: 34659439 DOI: 10.1155/2021/9003603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Abubakar MB, Usman D, El-Saber Batiha G, Cruz-Martins N, Malami I, Ibrahim KG, Abubakar B, Bello MB, Muhammad A, Gan SH, Dabai AI, Alblihed M, Ghosh A, Badr RH, Thangadurai D, Imam MU. Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies. Front Pharmacol 2021;12:629935. [PMID: 34012391 DOI: 10.3389/fphar.2021.629935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
4 Wu CY, Lin YS, Yang YH, Shu LH, Cheng YC, Liu HT. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2. Front Pharmacol 2020;11:584158. [PMID: 33390952 DOI: 10.3389/fphar.2020.584158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Oz M, Lorke DE, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther 2021;221:107750. [PMID: 33275999 DOI: 10.1016/j.pharmthera.2020.107750] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
6 Wu CY, Lin YS, Yang YH, Shu LH, Cheng YC, Liu HT. GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. Biomed Pharmacother 2020;132:110816. [PMID: 33049583 DOI: 10.1016/j.biopha.2020.110816] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kogan EA, Berezovsky YS, Protsenko DD, Bagdasaryan TR, Gretsov EM, Demura SA, Demyashkin GA, Kalinin DV, Kukleva AD, Kurilina EV, Nekrasova TP, Paramonova NB, Ponomarev AB, Radenska-lopovok SG, Semyonova LA, Tertychny AS. PATHOLOGICAL ANATOMY OF INFECTION CAUSED BY SARS-COV-2. Sud med (Online) 2020;6:8-30. [DOI: 10.19048/2411-8729-2020-6-2-8-30] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
8 Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol 2020;318:F1454-62. [PMID: 32412303 DOI: 10.1152/ajprenal.00160.2020] [Cited by in Crossref: 120] [Cited by in F6Publishing: 128] [Article Influence: 40.0] [Reference Citation Analysis]